Lenalidomide acts by a novel drug mechanism—modulation of the substrate specificity of the CRL4CRBN E3 ubiquitin ligase. In multiple myeloma, lenalidomide induces the ubiquitination …

Lenalidomide works through various mechanisms of actions that promote malignant cell death and enhance host immunity. 7 Available as oral capsules, lenalidomide is approved by the …

Lenalidomide, sold under the brand name Revlimid among others, is a medication used to treat multiple myeloma, smoldering myeloma, and myelodysplastic syndromes (MDS). [8] For …

2015年11月19日 · Lenalidomide is remarkably effective in multiple myeloma, with response rates for combined lenalidomide and dexamethasone exceeding 70% as a first-line therapy. 1-5 …

Lenalidomide is a 4-amino-glutamyl analogue of thalidomide that lacks the neurologic side effects of sedation and neuropathy and has emerged as a drug with activity against various …

Lenalidomide (LEN) is probably the most commonly used IMiD worldwide. However, despite its potent anti-MM activity, the vast majority of patients become LEN-resistant. In this review, we …

Recent preclinical and clinical findings suggest that the IMiDs® immunomodulatory compound lenalidomide has a dual mechanism of action, involving both a direct tumoricidal activity and …

2020年2月17日 · Lenalidomide, a thalidomide analogue, caused limb abnormalities in a developmental monkey study. Thalidomide is a known human teratogen that causes severe, …

2010年11月1日 · Lenalidomide has a dual mechanism of action involving a direct tumoricidal activity that leads to multiple myeloma cell death, and an immunomodulatory effect that keeps …

2009年8月12日 · Lenalidomide is a 4-amino-glutamyl analogue of thalidomide that lacks the neurologic side effects of sedation and neuropathy and has emerged as a drug with activity …